BMC
ACAD icon

Bear Mountain Capital’s Acadia Pharmaceuticals ACAD Stock Holding History

Bear Mountain Capital’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-7
Closed -$149 – 201
2025
Q3 		$149 Buy
+7
New +$166 ﹤0.01% 290

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Bear Mountain Capital's ACAD Position: Q4 2025 in Review

Bear Mountain Capital sold out of Acadia Pharmaceuticals (ACAD) in Q4 2025, closing a stake of 7 shares — an estimated $149 sold.

Bear Mountain Capital first reported a position in ACAD in Q3 2025 and held it in 1 quarter. The position peaked at $149 in Q3 2025. 336 funds tracked by Wall St. Rank hold ACAD as of Q4 2025.

  • Bear Mountain Capital reported no remaining Acadia Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Bear Mountain Capital sold 7 Acadia Pharmaceuticals shares in Q4 2025, an estimated $149.
  • Bear Mountain Capital first reported a position in Acadia Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Bear Mountain Capital's Acadia Pharmaceuticals position peaked at $149 in Q3 2025.
  • 336 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2025.

Based on Bear Mountain Capital's 13F filing for Q4 2025, filed 22 Jan 2026.